For the interim period of FY March 2027, revenue was 45,461,283 thousand yen, up 13.8% year-over-year. Operating income was 5,646,814 thousand yen, ordinary income was 5,191,672 thousand yen, and net income attributable to owners of parent for the interim period was 3,959,065 thousand yen, all showing substantial increases. Full-year forecasts were left unchanged: revenue 95,000 hundred million yen, operating income 13,000 hundred million yen, and net income attributable to owners of parent 10,000 hundred million yen. Dividends: interim dividend of 25 yen, full-year forecast revised to 26.00 yen. Information on the new drug pipeline and segment trends is also provided.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4559","jir_company_name":"Zeria Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4559-20261104-01.pdf","jir_short_summary":"For the interim period of FY March 2027, revenue was 45,461,283 thousand yen, up 13.8% year-over-year. Operating income was 5,646,814 thousand yen, ordinary income was 5,191,672 thousand yen, and net income attributable to owners of parent for the interim period was 3,959,065 thousand yen, all showing substantial increases. Full-year forecasts were left unchanged: revenue 95,000 hundred million yen, operating income 13,000 hundred million yen, and net income attributable to owners of parent 10,000 hundred million yen. Dividends: interim dividend of 25 yen, full-year forecast revised to 26.00 yen. Information on the new drug pipeline and segment trends is also provided.","jir_summary":"### Business Highlights\nConsolidated results for the second quarter show revenue of 45,461,283 thousand yen, a significant increase from the same period last year. Operating income was 5,646,814 thousand yen, ordinary income was 5,191,672 thousand yen, and net income attributable to owners of parent for the interim period was 3,959,065 thousand yen, all substantially exceeding the prior year. By segment, prescription pharmaceuticals were the core driver with strong performance both domestically and internationally, while consumer healthcare saw steady sales of some key products. Supplementary briefing materials and an earnings presentation will be held.\n\n### Outlook and Dividends\nFull-year outlook is maintained at revenue of 95,000 hundred million yen, operating income of 13,000 hundred million yen, ordinary income of 13,000 hundred million yen, net income attributable to owners of parent of 10,000 hundred million yen, and earnings per share of 226.86 yen. The year-end dividend forecast has been revised to 26.00 yen for FY2027. Foreign exchange impacts and other factors are not incorporated. Additional details on the new drug pipeline and continued domestic and overseas development status are provided.","jir_financial_highlights":"Revenue: 45,461,283 (YoY +13.8%)\nOperating Income: 5,646,814 (YoY +55.1%)\nOrdinary Income: 5,191,672 (YoY +95.4%)\nNet Income Attributable to Owners of Parent (interim): 3,959,065 (YoY +127.8%)","jir_category":"","jir_hashtags":"#ZeriaPharmaceutical, #FinancialResults, #InterimResults","jir_key_figures":"Revenue: 45,461,283 thousand yen (YoY +13.8%)\nOperating Income: 5,646,814 thousand yen (YoY +55.1%)\nNet Income Attributable to Owners of Parent (interim): 3,959,065 thousand yen (YoY +127.8%)","jir_meta_title":"Zeria Pharmaceutical Co., Ltd. \u2014 FY2027 Interim Financial Summary | Revenue Growth and Dividend Update","jir_meta_description":"Key points of Zeria Pharmaceutical Co., Ltd.'s FY2027 interim financial summary. Revenue 45,461,283 thousand yen; operating income 5,646,814 thousand yen; interim net income 3,959,065 thousand yen. Full-year outlook maintained and year-end dividend revised.","jir_og_title":"Zeria Pharmaceutical Co., Ltd. FY2027 Interim Financial Summary","jir_og_description":"Summary of interim strong performance, maintained full-year outlook, and revised year-end dividend. Includes trends in prescription pharmaceuticals and consumer healthcare segments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9548,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141412","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n